Breakthrough Glaucoma Research: Leveraging ANGPTL7 Humanized Models for Gene Therapy

Role of Advanced Models in Glaucoma Innovation

World Glaucoma Week serves as a critical global initiative to raise awareness about the leading cause of irreversible blindness. This year’s theme, “Uniting for a Glaucoma-Free World,” focuses on bringing communities worldwide together to fight against glaucoma-related vision loss ^[1]. This annual observance highlights a staggering public health challenge: currently, more than 80 million people are struggling with this "silent thief of sight." Without significant intervention, this figure is projected to climb to 111 million by 2040, placing an immense strain on global eye care systems and patient quality of life ^[2].

While traditional treatments focus on managing intraocular pressure (IOP), the therapeutic burden of lifelong eye drops and the limitations of surgery often lead to poor adherence and high costs-ranging up to $2,511 annually for advanced cases ^[3]. However, the tide is shifting toward gene therapy. By leveraging humanized and induced mouse models to decode complex polygenic and environmental drivers, researchers are developing neuroprotective treatments designed to fortify retinal ganglion cells. This shift from daily maintenance to potential "one-and-done" interventions offers a promising path toward a future where vision loss is no longer an inevitability.

Figure 1. Overview of proposed targets, delivery methods and vectors for glaucoma gene therapy ^[4].

Recapitulating Glaucoma Pathogenesis: Addressing Genetic Heterogeneity and IOP Regulation

Glaucoma is a progressive optic neuropathy characterized primarily by pathologically elevated intraocular pressure (IOP) and stands as the second leading cause of blindness worldwide. Clinically, managing IOP remains the only effective strategy for slowing disease progression. However, the genetic landscape of glaucoma is highly heterogeneous, with research from the International Glaucoma Genetics Consortium (IGGC) identifying over 300 genes associated with the risk of developing the condition ^[5].

Figure 2. Comparison between a normal eye and an eye with glaucoma ^[6].

Validating ANGPTL7 as a Potent Target for Sustained Intraocular Pressure Reduction

Angiopoietin-like 7 (ANGPTL7) has emerged as a promising therapeutic target for glaucoma. It has gained significant attention because it is highly expressed within the trabecular meshwork, which is the primary tissue responsible for aqueous humor outflow. Research indicates that elevated expression of ANGPTL7 correlates directly with increased intraocular pressure, and levels of this protein are significantly upregulated in the aqueous humor of patients with glaucoma. Genetic evidence further reveals that individuals carrying loss-of-function variants of the ANGPTL7 gene exhibit significantly lower intraocular pressure and a reduced risk of developing the disease ^[7]. Consequently, inhibiting ANGPTL7 to lower eye pressure represents a potential broad-spectrum treatment for glaucoma that could be effective regardless of a patient's specific genetic profile.

Figure 3. Mean intraocular pressure (IOP) is significantly lower in individuals carrying ANGPTL7 pLOF mutations compared to non-carriers ^[7].

Given these findings, ANGPTL7 inhibitors demonstrate significant therapeutic potential. Regeneron and Alnylam are currently collaborating to develop an siRNA therapy targeting ANGPTL7. They shared preclinical data for this program at the 2025 ARVO Annual Meeting, demonstrating the potential for significant intraocular pressure reduction ^[8]. Separately, Broadwing Bio, a joint venture between Alloy Therapeutics and Maze Therapeutics, is advancing a targeted antibody ^[9]. These molecules are in the early stages of development and have demonstrated potential for slowing the progression of glaucoma.

Figure 4. ANGPTL7 antibodies caused a increase in outflow facility and decrease in IOP ^[9].

Cyagen: Comprehensive Solutions for Ophthalmic Disease Research

Precision medicine is only as effective as the models used to test it. To bridge the gap between the lab and the clinic, Cyagen has developed the huANGPTL7 humanized mouse (Product No. C001789), featuring a complete genomic replacement of the ANGPTL7 gene from the 5' UTR to the 3' UTR. For researchers in drug discovery—particularly those working with siRNA—this level of gene fidelity is vital. By keeping the full human non-coding sequences intact, our platform provides the exact binding sites and regulatory elements needed for high-stakes validation, offering a highly relevant environment for testing genetic therapies.

True breakthroughs require more than just the right model; they require expert execution. Cyagen’s CRO services seamlessly integrate these humanized models with established glaucoma protocols, including Magnetic Bead Occlusion, Optic Nerve Crush, and Ischemia-Reperfusion. This "Model + Service" approach allows teams to test human-specific therapeutics within a reliable and controlled disease environment.

To further support these efforts, Cyagen has established a professional ophthalmic pharmacodynamics platform. We provide a complete workflow that ranges from ocular drug delivery and in vivo functional and imaging tests to tissue collection, pathology, and molecular-level analysis. This integrated, one-stop solution is designed to streamline the preclinical research process for new ophthalmic drugs.

Conclusion: Integrating Multi-Target Models for Glaucoma Gene Therapy

As World Glaucoma Week highlights the urgent global need for innovation, the transition from lifelong symptom management to targeted genetic intervention marks a pivotal shift in ophthalmic medicine. The emergence of ANGPTL7 as a high-conviction therapeutic target, supported by robust genetic data and emerging siRNA and antibody pipelines, offers a concrete path toward reducing the burden of irreversible blindness.

By integrating these sophisticated models with specialized CRO services, we can more accurately bridge the gap between preclinical discovery and clinical success. Together, these advancements in genomic medicine and high-fidelity research platforms are not just "uniting for a glaucoma-free world," they are providing the technical foundation to make it a reality.